The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) to treat advanced neuroendocrine ...

Proteins in the sheath of cellular protrusions control how effectively cells can adhere to surfaces. Biological cells often ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Approval was based on findings from the pivotal CABINET trial showing improved PFS and response rates vs placebo.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...

Also known as type 1.5 diabetes, here’s what to know about the onset, symptoms, diagnosis, and treatment options for latent ...

Exelixis has won U.S. Food and Drug Administration expanded approval of its Cabometyx cancer drug for certain patients with advanced neuroendocrine tumors.

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.